Toronto Dominion Bank Buys New Stake in Amedisys, Inc. (NASDAQ:AMED)

Toronto Dominion Bank acquired a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 174,035 shares of the health services provider's stock, valued at approximately $15,801,000. Toronto Dominion Bank owned 0.53% of Amedisys as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. Sherbrooke Park Advisers LLC purchased a new position in Amedisys in the fourth quarter worth approximately $380,000. Quantinno Capital Management LP grew its stake in shares of Amedisys by 48.1% in the fourth quarter. Quantinno Capital Management LP now owns 59,911 shares of the health services provider's stock valued at $5,439,000 after buying an additional 19,454 shares in the last quarter. Nomura Holdings Inc. acquired a new stake in shares of Amedisys in the fourth quarter valued at $395,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Amedisys in the fourth quarter valued at $295,000. Finally, Moore Capital Management LP acquired a new stake in shares of Amedisys in the fourth quarter valued at $817,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Stephens reaffirmed an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th. Finally, Wall Street Zen cut Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $100.75.

Amedisys Stock Down 0.1%

AMED traded down $0.13 on Friday, hitting $93.43. 128,989 shares of the company were exchanged, compared to its average volume of 417,944. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The company has a market cap of $3.07 billion, a price-to-earnings ratio of 37.08, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $93.36 and a two-hundred day moving average price of $91.53.

Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. During the same period in the previous year, the firm posted $1.03 EPS. Amedisys's revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.